286 related articles for article (PubMed ID: 19627579)
1. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.
Moran EM; Mullan R; McCormick J; Connolly M; Sullivan O; Fitzgerald O; Bresnihan B; Veale DJ; Fearon U
Arthritis Res Ther; 2009; 11(4):R113. PubMed ID: 19627579
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures.
Fearon U; Mullan R; Markham T; Connolly M; Sullivan S; Poole AR; FitzGerald O; Bresnihan B; Veale DJ
Arthritis Rheum; 2006 Oct; 54(10):3152-62. PubMed ID: 17009243
[TBL] [Abstract][Full Text] [Related]
3. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion.
Tetlow LC; Woolley DE
Arthritis Res; 1999; 1(1):63-70. PubMed ID: 11056661
[TBL] [Abstract][Full Text] [Related]
4. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
[TBL] [Abstract][Full Text] [Related]
5. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases.
Sun S; Bay-Jensen AC; Karsdal MA; Siebuhr AS; Zheng Q; Maksymowych WP; Christiansen TG; Henriksen K
BMC Musculoskelet Disord; 2014 Mar; 15():93. PubMed ID: 24641725
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.
Barksby HE; Milner JM; Patterson AM; Peake NJ; Hui W; Robson T; Lakey R; Middleton J; Cawston TE; Richards CD; Rowan AD
Arthritis Rheum; 2006 Oct; 54(10):3244-53. PubMed ID: 17009259
[TBL] [Abstract][Full Text] [Related]
7. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
8. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.
Hui W; Rowan AD; Richards CD; Cawston TE
Arthritis Rheum; 2003 Dec; 48(12):3404-18. PubMed ID: 14673992
[TBL] [Abstract][Full Text] [Related]
10. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint.
Cawston TE; Curry VA; Summers CA; Clark IM; Riley GP; Life PF; Spaull JR; Goldring MB; Koshy PJ; Rowan AD; Shingleton WD
Arthritis Rheum; 1998 Oct; 41(10):1760-71. PubMed ID: 9778217
[TBL] [Abstract][Full Text] [Related]
11. Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Thwin MM; Douni E; Arjunan P; Kollias G; Kumar PV; Gopalakrishnakone P
Arthritis Res Ther; 2009; 11(5):R138. PubMed ID: 19765281
[TBL] [Abstract][Full Text] [Related]
12. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation.
Sondergaard BC; Henriksen K; Wulf H; Oestergaard S; Schurigt U; Bräuer R; Danielsen I; Christiansen C; Qvist P; Karsdal MA
Osteoarthritis Cartilage; 2006 Aug; 14(8):738-48. PubMed ID: 16563811
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro.
Langdon C; Leith J; Smith F; Richards CD
Arthritis Rheum; 1997 Dec; 40(12):2139-46. PubMed ID: 9416850
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Catrina AI; Lampa J; Ernestam S; af Klint E; Bratt J; Klareskog L; Ulfgren AK
Rheumatology (Oxford); 2002 May; 41(5):484-9. PubMed ID: 12011369
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo model exhibits protective effects of sesamin against destruction of cartilage induced with a combination of tumor necrosis factor-alpha and oncostatin M.
Khansai M; Boonmaleerat K; Pothacharoen P; Phitak T; Kongtawelert P
BMC Complement Altern Med; 2016 Jul; 16():205. PubMed ID: 27400672
[TBL] [Abstract][Full Text] [Related]
17. Increased CD40 expression on articular chondrocytes from patients with rheumatoid arthritis: contribution to production of cytokines and matrix metalloproteinases.
Gotoh H; Kawaguchi Y; Harigai M; Hara M; Saito S; Yamaguchi T; Shimada K; Kawamoto M; Tomatsu T; Kamatani N
J Rheumatol; 2004 Aug; 31(8):1506-12. PubMed ID: 15290728
[TBL] [Abstract][Full Text] [Related]
18. Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response.
Furuzawa-Carballeda J; Macip-Rodríguez PM; Cabral AR
Clin Exp Rheumatol; 2008; 26(4):554-60. PubMed ID: 18799084
[TBL] [Abstract][Full Text] [Related]
19. In vitro model for the analysis of synovial fibroblast-mediated degradation of intact cartilage.
Pretzel D; Pohlers D; Weinert S; Kinne RW
Arthritis Res Ther; 2009; 11(1):R25. PubMed ID: 19226472
[TBL] [Abstract][Full Text] [Related]
20. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
